AIkido Pharma Gets $8/Share Buyout Offer From Shalom Auerbach >AIKI

Dow Jones

2022/08/10

By Colin Kellaher

AIkido Pharma Inc. on Wednesday said it received an unsolicited offer from shareholder Shalom Auerbach to acquire the company for about $42 million, or $8 a share.

The offer represents a 28% premium to Tuesday's closing price of $6.25 for the New York biotechnology company.

AIkido said its board will carefully review the proposal to determine the course of action it believes is in the best interest of the company and its shareholders, adding that it will respond in due course.

In a letter to AIkido's board, Mr. Auerbach said he beneficially owns a roughly 3.8% stake, and that he would be able to fund a transaction using cash on hand and external financing.

Write to Colin Kellaher at colin.kellaher@wsj.com

$(END)$ Dow Jones Newswires

August 10, 2022 08:48 ET (12:48 GMT)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2258216882"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2258216882\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2258216882?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-08-10 20:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2258216882","market":"us","top_or_hot":-1,"title":"AIkido Pharma Gets $8/Share Buyout Offer From Shalom Auerbach >AIKI","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre>\n \n</pre>\n<p>\n  AIkido Pharma Inc. on Wednesday said it received an unsolicited offer from shareholder Shalom Auerbach to acquire the company for about $42 million, or $8 a share. \n</p>\n<p>\n  The offer represents a 28% premium to Tuesday's closing price of $6.25 for the New York biotechnology company. \n</p>\n<p>\n  AIkido said its board will carefully review the proposal to determine the course of action it believes is in the best interest of the company and its shareholders, adding that it will respond in due course. \n</p>\n<p>\n  In a letter to AIkido's board, Mr. Auerbach said he beneficially owns a roughly 3.8% stake, and that he would be able to fund a transaction using cash on hand and external financing. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/END\">$(END)$</a> Dow Jones Newswires\n</p>\n<p>\n  August 10, 2022 08:48 ET (12:48 GMT)\n</p>\n<p>\n  Copyright (c) 2022 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AIkido Pharma Gets $8/Share Buyout Offer From Shalom Auerbach >AIKI</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAIkido Pharma Gets $8/Share Buyout Offer From Shalom Auerbach >AIKI\n</h2>\n<h4 class=\"meta\">\n<div class=\"head\" \">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time smaller\">2022-08-10 20:48</p>\n</div>\n</div>\n</h4>\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre>\n \n</pre>\n<p>\n  AIkido Pharma Inc. on Wednesday said it received an unsolicited offer from shareholder Shalom Auerbach to acquire the company for about $42 million, or $8 a share. \n</p>\n<p>\n  The offer represents a 28% premium to Tuesday's closing price of $6.25 for the New York biotechnology company. \n</p>\n<p>\n  AIkido said its board will carefully review the proposal to determine the course of action it believes is in the best interest of the company and its shareholders, adding that it will respond in due course. \n</p>\n<p>\n  In a letter to AIkido's board, Mr. Auerbach said he beneficially owns a roughly 3.8% stake, and that he would be able to fund a transaction using cash on hand and external financing. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/END\">$(END)$</a> Dow Jones Newswires\n</p>\n<p>\n  August 10, 2022 08:48 ET (12:48 GMT)\n</p>\n<p>\n  Copyright (c) 2022 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"http://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2258216882","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2258216882","pubTimestamp":1660135680,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"AIkido Pharma Inc. on Wednesday said it received an unsolicited offer from shareholder Shalom Auerbach to acquire the company for about $42 million, or $8 a share.The offer represents a 28% premium to Tuesday's closing price of $6.25 for the New York biotechnology company.AIkido said its board will carefully review the proposal to determine the course of action it believes is in the best interest of the company and its shareholders, adding that it will respond in due course.In a letter to AIkido","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技"},"translate_title":"合气道制药从Shalom Auerbach>Aiki获得8美元/股的收购要约","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AIKI":1},"content_text":"By Colin Kellaher \n\n\n \n\n\n  AIkido Pharma Inc. on Wednesday said it received an unsolicited offer from shareholder Shalom Auerbach to acquire the company for about $42 million, or $8 a share. \n\n\n  The offer represents a 28% premium to Tuesday's closing price of $6.25 for the New York biotechnology company. \n\n\n  AIkido said its board will carefully review the proposal to determine the course of action it believes is in the best interest of the company and its shareholders, adding that it will respond in due course. \n\n\n  In a letter to AIkido's board, Mr. Auerbach said he beneficially owns a roughly 3.8% stake, and that he would be able to fund a transaction using cash on hand and external financing. \n\n\n \n\n\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n\n\n \n\n\n$(END)$ Dow Jones Newswires\n\n\n  August 10, 2022 08:48 ET (12:48 GMT)\n\n\n  Copyright (c) 2022 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}